Jie-Si Luo
Overview
Explore the profile of Jie-Si Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
366
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan Z, Yang L, Chen Y, Wan W, Zhou D, Mai H, et al.
Ther Adv Hematol
. 2025 Jan;
16():20406207241311774.
PMID: 39781038
Background: Treatment outcomes for acute promyelocytic leukemia (APL) have improved with all-trans-retinoic acid and arsenic trioxide, yet relapse remains a concern, especially in pediatric patients. The prognostic value of minimal...
2.
Fan Z, Huang X, Huang D, Luo J, Su J, Zhang X, et al.
Trials
. 2024 Dec;
25(1):819.
PMID: 39695871
Background: The treatment of all-trans retinoic acid (ATRA) and arsenical agent has revolutionarily improved the prognosis of acute promyelocytic leukemia (APL) both in adults and children. Nevertheless, coagulation disorder and...
3.
Fan Z, Lin W, Liang C, Li Y, Peng C, Luo J, et al.
Hum Exp Toxicol
. 2024 Nov;
43:9603271241303030.
PMID: 39586583
Background: Acute lymphoblastic leukemia (ALL) is one of the most common pediatric cancers, characterized by the malignant proliferation of leukemic cells. Despite advancements in treatment, the prognosis for refractory and...
4.
Cheng Y, Fan Z, Liang C, Peng C, Li Y, Wang L, et al.
Technol Cancer Res Treat
. 2024 May;
23:15330338241248576.
PMID: 38693824
Acute myeloid leukemia (AML) is a type of blood cancer characterized by excessive growth of immature myeloid cells. Unfortunately, the prognosis of pediatric AML remains unfavorable. It is imperative to...
5.
Peng C, Fan Z, Luo J, Wang L, Li Y, Liang C, et al.
Technol Cancer Res Treat
. 2024 Jan;
23:15330338231223080.
PMID: 38179723
Background: Acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 gene internal tandem duplication (FLT3-ITD) mutations has a poor prognosis. The combination of arsenic trioxide (ATO) and all-trans retinoic acid...
6.
Huang D, Yang L, Chen Y, Wan W, Zhou D, Mai H, et al.
Blood Cancer J
. 2023 Dec;
13(1):178.
PMID: 38052803
Realgar-Indigo naturalis formula (RIF), an oral traditional Chinese medicine mainly containing Realgar (AsS), is highly effective in treating adult acute promyelocytic leukemia (APL). However, the treatment efficacy and safety of...
7.
Luo J, Zhang X, Huang D, Chen Y, Wan W, Mai H, et al.
Ann Hematol
. 2023 May;
102(7):1713-1721.
PMID: 37199788
Realgar-Indigo naturalis formula (RIF), with AS as a major ingredient, is an oral arsenic used in China to treat pediatric acute promyelocytic leukemia (APL). The efficacy of RIF is similar...
8.
Massudi H, Luo J, Holien J, Gadde S, Krishan S, Herath M, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980710
MYCN is a major oncogenic driver for neuroblastoma tumorigenesis, yet there are no direct MYCN inhibitors. We have previously identified PA2G4 as a direct protein-binding partner of MYCN and drive...
9.
Tang Y, Su J, Luo J, Zhang L, Zheng L, Liang C, et al.
Recent Pat Anticancer Drug Discov
. 2022 Dec;
18(4):538-548.
PMID: 36503469
Background: Acute lymphoblastic leukemia with MLL/AF4 rearrangement remains a major hurdle to improving outcomes. Gene network and circRNAs have been found to participate in tumorigenesis, while their roles in leukemia...
10.
Seneviratne J, Carter D, Mittra R, Gifford A, Kim P, Luo J, et al.
Int J Cancer
. 2022 Nov;
152(7):1399-1413.
PMID: 36346110
The mitochondrion is a gatekeeper of apoptotic processes, and mediates drug resistance to several chemotherapy agents used to treat cancer. Neuroblastoma is a common solid cancer in young children with...